In the long struggle between human ingenuity and cancer's capacity for evasion, researchers at City of Hope in Los Angeles have opened a new front: immune cells that can be reprogrammed after they are already inside the body. Where current CAR T therapies are fixed at the moment of infusion—unable to respond when tumors mutate and hide—the meCAR T platform introduces adaptability as a core feature of treatment. Like a living software system, it invites the possibility that medicine need not anticipate every threat in advance, but can instead learn and respond alongside the disease.